PARP inhibitors (PARPi) have transformed the treatment landscape for metastatic castration-resistant prostate cancer (mCRPC) with BRCA1/2 mutations, yet resistance inevitably emerges. Until now, most ...
A research team led by Dr. Yuanliang Zhai from the School of Biological Sciences, The University of Hong Kong (HKU), and his collaborators from The Hong Kong University of Science and Technology ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results